BiotechTube
BrainChild Bio

BrainChild Bio

San Diego, United States· Est.
brainchildbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

BrainChild Bio is a private, clinical-stage biotech based in San Diego, founded in 2018, developing next-generation CAR-T therapies for CNS tumors. The company's core innovation is a platform for repetitive, direct cerebroventricular delivery of engineered T-cells via an implantable shunt, combined with synthetic biology modules for multiplexed targeting, potency enhancement, and conditional control. With a pivotal trial planned for its lead pediatric program in DIPG and a pipeline targeting broader CNS oncology, BrainChild Bio aims to address significant unmet needs in both pediatric and adult neuro-oncology.

OncologyNeuroscienceRare Disease

Technology Platform

A next-generation CAR-T platform for CNS tumors featuring locoregional delivery via implantable shunt for recursive dosing, and synthetic biology modules for multiplexed antigen targeting, potency enhancement (PotencyPlus), and small-molecule controlled activity (DrugON).

Funding History

2
Total raised:$3.5M
Grant$500K
Seed$3M

Opportunities

The company addresses massive unmet needs in fatal pediatric (DIPG) and adult (glioblastoma, brain metastases) CNS cancers with no effective therapies.
Success in its pivotal DIPG trial would validate its unique delivery and engineering platform, enabling rapid expansion into larger adult oncology markets and creating significant partnership potential.

Risk Factors

High clinical risk associated with novel, locally delivered CAR-T in the complex brain environment.
The small initial pediatric market (DIPG) presents commercial challenges, requiring successful expansion to adult indications for financial viability.
The technology faces biological hurdles like the immunosuppressive CNS tumor microenvironment and antigen escape.

Competitive Landscape

Competition includes other biotechs developing CAR-Ts for solid tumors and CNS cancers (e.g., Mustang Bio, Cartesian Therapeutics) and companies exploring alternative immunotherapies. BrainChild's key differentiators are its direct CNS delivery method, pediatric-first focus, and integrated suite of synthetic biology controls, positioning it uniquely if clinically validated.

More companies in Cell & Gene Therapy →More companies in United States →